Loss of ECRG4 expression decreases neutrophil mobilization from bone marrow reserves. by Katie D. Pool (20141584)

Subjects:

Differentially expressed genes (DEGs)^a showing the greatest fold changes from each potato tissue: 10 with greatest increase in expression and 10 with greatest decrease in expression. by Margaret A. Carpenter (6104180)

“…<p>Differentially expressed genes (DEGs)^a showing the greatest fold changes from each potato tissue: 10 with greatest increase in expression and 10 with greatest decrease in expression.…”

Analysis of tea output value distribution and growth- decrease rate of provinces. by Kun Qin (177235)

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

Correlation of differential metabolites. by Jun Sun (48981)

Subjects:

RDA and pearson correlation analysis of soil bacterial communities and soil environmental factors. by Jun Sun (48981)

Subjects:

Femur length anomalies tend to decrease with later phenology (greater day of year of adulthood anomaly) regardless of elevation or species’ seasonal timing. by César R. Nufio (11646271)

Biases in larger populations. by Sander W. Keemink (21253563)

“…<p>(<b>A</b>) Maximum absolute bias vs the number of neurons in the population for the Bayesian decoder. Bias decreases with increasing neurons in the population. …”

TITAN decreaser diatom heatmap. by Brent J. Bellinger (21156150)

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

“…The locomotion values (traces and metrics) are in arbitrary units with larger integers representing a greater displacement of the spherical treadmill, the hemodynamic (Hbt) values (traces and metrics) are a percentage change from the normalised baseline (prior to stimulus presentation), and the corresponding time series vector is presented in seconds. …”

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects:

Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Participant demographics. * P-values were determined using Fisher-Freeman-Halton test when contingency tables are larger than 2 × 2. by Elie Mulhem (22537863)